Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
X4 Pharmaceuticals Inc (X4 Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on rare diseases of the immune system. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of warts, hypogammaglobulinemia, immunodeficiency and myelokathexis (WHIM) syndrome. It also offers X4Connect for patients and their caregivers dedicated support throughout their XOLREMDI treatment journey, including disease and treatment-related resources, insurance support, and copay assistance. The company markets products under XOLREMDI brand name. X4 Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
4th Floor, 61 North Beacon Street, Boston, Massachusetts, 02134
Website
www.x4pharma.com
Telephone
1 857 5298300
No of Employees
45
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
XFOR (NASD)
Revenue (2024)
$35.1M
1273.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-111.5%
(2024 vs 2023)
Market Cap*
$304.4M
Net Profit Margin (2024)
XYZ
84.6%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| XOLREMDI (Mavorixafor): | XOLREMDI |
| WHIM Syndrome | X4Connect |
| Chronic Neutropenic Disorders | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | X4 Pharmaceuticals Inc | Pfizer Inc | Novartis AG | Y-mAbs Therapeutics Inc | Crescent Biopharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Boston | New York City | Basel | Princeton | Waltham |
| State/Province | Massachusetts | New York | Basel-Stadt | New Jersey | Massachusetts |
| No. of Employees | 45 | 75,000 | 75,267 | 107 | 44 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Adam R. Craig, MD, Ph.D | Chairman | Executive Board | 2025 | 60 |
| David Kirske | Secretary; Chief Financial Officer | Senior Management | 2025 | 72 |
| John Volpone | President; Chief Operating Officer | Senior Management | 2025 | 51 |
| Francoise de Craecker | Director | Non Executive Board | 2021 | 64 |
| Michael S. Wyzga | Director | Non Executive Board | 2018 | 71 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer